Canada markets close in 42 minutes

TTOO May 2024 1.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 11:43AM EDT. Market open.
Full screen
Previous Close0.0500
Open0.0500
Bid0.0000
Ask0.0000
Strike1.00
Expire Date2024-05-17
Day's Range0.0500 - 0.0500
Contract RangeN/A
Volume34
Open Interest173
  • GlobeNewswire

    T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of

  • GlobeNewswire

    T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock

    LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that entities affiliated with CRG Servicing LLC (“CRG”) have converted Series A and Series B Convertible Preferred Stock to Common Stock. On May 9, 2024, the Company amended and restated each of the Series A Certificate of Designation and the Series B Certificate of Designation, in each c

  • GlobeNewswire

    T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease

    Advances plan to launch T2Lyme Panel for detection of early Lyme diseaseFiled Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has signed a non-binding letter of intent (“LOI”) to enter into a strat